BioSpace News Archive

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).

ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2022.

Rocket Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501.

STAAR Surgical Company today announced that it will release financial results for the fourth quarter and fiscal year ended December 30, 2022, on Tuesday, February 21, 2023 after the market close.

Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET.

Marinus Pharmaceuticals, Inc. today announced that management will present and participate during the following conferences in February and March.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:40 p.m. Eastern time.

Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the fourth quarter and full year 2022.

Twist Bioscience Corporation today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications, at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting in Hollywood, Florida.